US 12,257,292 B2
Enhanced delivery of antioxidants for treatment of central nervous system disorders involving oxidative stress
Ryan Kole, Glencoe, IL (US); John Marshall, Chicago, IL (US); and Meriel Owen, New York, NY (US)
Assigned to BEYOND BARRIERS THERAPEUTICS, INC., Glencoe, IL (US)
Filed by Beyond Barriers Therapeutics, Inc., Glencoe, IL (US)
Filed on Dec. 15, 2022, as Appl. No. 18/082,379.
Application 18/082,379 is a division of application No. 16/859,722, filed on Apr. 27, 2020, granted, now 11,612,642.
Application 16/859,722 is a continuation in part of application No. PCT/US2018/057983, filed on Oct. 29, 2018.
Claims priority of provisional application 62/578,061, filed on Oct. 27, 2017.
Prior Publication US 2023/0118328 A1, Apr. 20, 2023
Int. Cl. A61K 9/00 (2006.01); A61K 31/122 (2006.01); A61K 31/16 (2006.01); A61K 31/198 (2006.01); A61K 31/40 (2006.01); A61K 31/573 (2006.01); A61K 31/724 (2006.01); A61K 38/22 (2006.01); A61K 38/44 (2006.01); A61K 38/48 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/4886 (2013.01) [A61K 9/0043 (2013.01); A61K 31/122 (2013.01); A61K 31/16 (2013.01); A61K 31/198 (2013.01); A61K 31/40 (2013.01); A61K 31/573 (2013.01); A61K 31/724 (2013.01); A61K 38/22 (2013.01); A61K 38/446 (2013.01); A61K 45/06 (2013.01)] 19 Claims
 
1. A kit for treating a subject having a central nervous system (CNS) disorder, the kit comprising:
(a) at least one antioxidant compound or a pharmaceutically acceptable salt thereof, wherein the at least one antioxidant compound comprises N-acetylcysteine (NAC),
(b) an intranasal delivery device, and
(c) an outer carrying case for carrying the intranasal delivery device, wherein the outer carrying case is adapted to protect the at least one antioxidant compound from severe conditions.